Abivax: Wall Street Catches Up to the Data
Abivax stock surged over 40% after positive Phase 3 data on ulcerative colitis drug Obefazimod and a $920 million share offering that underwriters fully exercised, signaling strong institutional…
Read the full articleYou might also wanna read
Abivax’s $920M Wall Street Haul Follows Cancer Risk Resolution, Paving Way for US Launch
Abivax clears safety concerns in ulcerative colitis trial, secures record $920M US offering, sending shares to fresh highs and setting the s
Abivax cashes in on investor enthusiasm with €807m raise - European Biotechnology Magazine
Abivax has raised $920m (€807m) in gross proceeds through a US public offering, only days after new obefazimod data helped calm investor con
Abivax Secures $920M for IBD Drug US Launch - allsci.com
Abivax closes $920M public offering to fund US commercialization of inflammatory bowel disease candidate. Extends cash runway through Q4 202
Abivax CEO says $920M raise lets it launch its bowel disease drug in the U.S. solo
The French biotech plans to use proceeds to commercialize obefazimod in the U.S. through 2029, CEO Marc de Garidel told CNBC
Quartz·23h agoAbivax CEO says $920M raise lets it launch its bowel disease drug in the U.S. solo
The French biotech plans to use proceeds to commercialize obefazimod in the U.S. through 2029, CEO Marc de Garidel told CNBC
qz.com·23h agoAbivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Abivax's latest funding round allows the biotech to move toward a U.S. launch of its bowel disease drug without backing from Big Pharma, its
Abivax CEO says $920M raise lets it launch its bowel disease drug ...
8 hours ago ... Abivax enough financial runway to bring its bowel disease drug to the American market independently, without relying on a pa
Comments
Sign in to join the conversation.
No comments yet. Be the first.